Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration

Intra-tumor delivery of zoledronate mitigates metastasis-induced osteolysis superior to systemic administration

Bisphosphonates (BPs) have recently been shown to have direct anti-tumor properties. Systemic treatment with BPs can have multiple adverse effects such as osteonecrosis of the jaw and BP induced bone fracturing and spine instability. While benefits of systemic BP treatments may outweigh risks, local...

Full description

Bibliographic Details
Main Authors: Anas Nooh, Yu Ling Zhang, Daisuke Sato, Derek H. Rosenzweig, Sébastien Tabariès, Peter Siegel, Jake E. Barralet, Michael H. Weber
Format: Article
Language:English
Published: Elsevier 2017-03-01
Series:Journal of Bone Oncology
Subjects:
Bone metastases
Xenograft
Bisphosphonates
Osteolysis
Local treatment
Cancer pain
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137416301038

Internet

http://www.sciencedirect.com/science/article/pii/S2212137416301038

Similar Items